InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$104.88

2026-10-16

Market Cap

$181.5B

Volume

8.0M

52-Wk High

$132.03

52-Wk Low

$81.97

Trailing PE

33.7

P/S

3.90

Gross Margin

56.8%

Net Margin

11.6%

ROE

11%

ROIC

6%

Piotroski

5/9

Altman Z

3.3

1-Yr Return

-17.8%

5-Yr Return

+38.5%

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, MÃ©niÃ¨re's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

SectorHealthcareIndustryMedical - DevicesExchangeNYSEMarket Cap$181.5BEmployees115,000 (SEC-filed)CEORobert FordIPO1980-03-17CountryUS

100 Abbott Park Road, Abbott Park, IL 60064-6400 · Tel 224 667 6100 · abbott.com

INSIDERSTREET SCORE57 / 100Street mean $123.67 (6 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALTWO-WAY FLOW$1.3M buys against $47.3M sells / 6 mo

1 Year vs S&P 500 · ABT -17.8% · S&P 500 +15.9% · spread -33.7pp

7 Years vs S&P 500 · ABT +38.5% · S&P 500 +189.9% · spread -151.4pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE57of 100

Score Breakdown

Profitability	46/100
Growth	28/100
Momentum	60/100
Quality	70/100
Earnings Quality	72/100
Balance Sheet	62/100
Value	49/100
Risk (safety)	80/100
Overall	56.6/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
MDT	64
SYK	74
BSX	67
EW	65
DXCM	81
GILD	44
ABT	57

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 67 in 24 Q3, latest 57 — -10 since. Fell in 3 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY57 / 100IS Score 56.6 / 100 · -10.2 from peak of 67

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 78 / 100 · Power +55 · 19 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

Both readings sit above the midpoint — business quality at 57 and price structure at 78 out of 100 — so they are not in conflict. The fundamentals and the tape are saying the same thing, which is the case in which either one alone would have been enough.

Trigger	Where it stands now	What it would mean
IS Score reaches 75 and holds two consecutive quarters	now 56.6	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 64 → 58 → 55 → 57	the direction matters more than the level
Technical vote share back above 50%	now 91%	price structure no longer broken
Institutional holder count rises two quarters running	peak 3,293 → now 2,987	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score4 of 4top 0% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)13 buys2026-09-18

Insider Buys (180d)3$1.3M

ETF Funds (30d)1520 up / 1228 downnet +292 funds

Institutions Added (13F)-134managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 3,293 · latest 2,987 (-306 from peak).

Quarter	Holders	13F shares	Value	Reported own%
2026 Q2	2,987	1437.6M	$126.9B	82.5%
2026 Q1	3,121	1376.2M	$138.0B	79.0%
2025 Q4	3,293	1430.4M	$168.2B	82.1%
2025 Q3	3,183	1358.1M	$175.5B	77.9%
2025 Q2	3,197	1379.8M	$183.6B	79.2%
2025 Q1	3,178	1374.8M	$179.5B	78.9%
2024 Q4	3,075	1351.7M	$150.6B	77.5%
2024 Q3	2,904	1307.6M	$147.3B	75.0%
2024 Q2	2,875	1320.5M	$135.9B	75.8%
2024 Q1	2,918	1307.4M	$146.8B	75.0%
2023 Q4	2,894	1307.7M	$143.1B	75.0%
2023 Q3	2,688	1297.9M	$125.2B	74.5%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Stratton John G	director	2026-09-30	A-Award	397	—	14,499
Gonzalez Patricia Paola	director	2026-09-30	A-Award	333	—	6,331
Conroy Kevin T	director	2026-09-30	A-Award	318	—	551
Ahuja Nita	director	2026-09-30	A-Award	318	—	771
Roman Michael F	director	2026-09-30	A-Award	381	—	7,166
Conroy Kevin T	director	2026-09-23	TAX W/H	52,507	$5.46M	81,230
Mccoy John A. Jr.	VICE PRESIDENT AND CONTROLLER	2026-09-02	SELL	27	$0.00M	24,549
Boudreau Philip P	EVP AND CFO	2026-09-01	TAX W/H	388	$0.04M	70,784

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	10	408,908	$47.3M	Counted
P — Open-market purchases	3	14,200	$1.3M	Counted
M — Exercises (paired A/D)	2	398,832	$21.5M	None — mechanics
F — Tax withholding	15	124,331	$13.8M	None — compensation

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalTwo-Way Flow

Open-Market Sells$47.3M10 txns / 6 mo

Open-Market Buys$1.3M3 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-09-02	John A. Mccoy, Jr.	27	$0.0M
2026-08-25	Robert B. Ford	398,832	$46.2M
2026-08-11	Louis H. Morrone	5,850	$0.6M
2026-05-15	Robert J. Alpern	7,587	$0.6M
Trailing 12 mo	12 filings	447,292	$51M

Filed	Form	Reporting person	% of class	Shares
2026-03-26	SCHEDULE 13G/A	The Vanguard Group	—	exit/reporting change
2025-12-03	SCHEDULE 13G/A	The Vanguard Group	10.05%	174.9M sh

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Member	Chamber	Trade	Size band	Traded	Disclosed
Gilbert Cisneros	House	BUY	$1,001 - $15,000	2026-09-18	2026-10-13
Gilbert Cisneros	House	BUY	$1,001 - $15,000	2026-09-18	2026-10-12
Ro Khanna	House	BUY	$1,001 - $15,000	2026-09-04	2026-10-09
Shelley Moore Capito	Senate	SELL	$1,001 - $15,000	2025-02-24	2025-03-06
Shelley Moore Capito	Senate	SELL	$1,001 - $15,000	2025-02-24	2025-03-05
Shelley Moore Capito	Senate	SELL	$1,001 - $15,000	2025-02-24	2025-03-05

House 12-Mo74 trades26 purchases

Senate 12-Mo0 tradesNone purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)3,121

13F Shares1.38B79.0% of shares out

New / Closed184 / 295positions, QoQ

Increased / Reduced1,118 / 1,443positions, QoQ

Put/Call (13F)0.94option positions

Free Float99.4%1.72B sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Assenagon Asset Management S.A.	5.2M	$513M
Davenport & Co Llc	1.8M	$180M
Ninety One Uk Ltd	1.8M	$177M
Wealth Enhancement Advisory Servic	1.5M	$137M
Deprince Race & Zollo Inc	558,162	$55M
Fjarde Ap-Fonden /Fourth Swedish N	554,382	$55M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.2%	$5.4B
VSMPX	0.2%	$5.4B
VTSAX	0.2%	$5.4B
VTI	0.2%	$5.4B
VFIAX	0.3%	$4.5B
VFFSX	0.3%	$4.5B

13F Filers Holding ABT — quarterly

Institutional Put/Call — quarterly

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session40.3%2026-10-15

20-Day Avg44.4%50-day 46.5%

TrendFalling20d vs 50d

By Market CenterQ: 40% · N: 48% · B: 41%latest session

Weekly Notional ($B)

Where ABT Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	12.2M	77 sh
Ubsa Ubs Ats	11.6M	87 sh
Ebxl Level Ats	8.5M	72 sh
Sgmt Sigma X2	6.8M	88 sh
Bids Bids Ats	6.5M	653 sh
Mlix Instinct X	4.4M	110 sh

Where a dollar of Abbott Laboratories revenue goes. All values FY2025 filings, live.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Region	Revenue	Share
UNITED STATES	$17.1B	40%
Non-US	$16.0B	37%
D [E]	$2.8B	6%
C [N]	$1.9B	4%
I [N]	$1.9B	4%
C [H]	$1.9B	4%
J [P]	$1.5B	3%

ABT (live moat model)Peer median: MDT · SYK · BSX · EW · DXCM

Component scores from the live moat model. Peer median illustrative.

Moat score 55/100 — Weak; primary source Efficient Scale.

3.8 · Employees (SEC filings)

Officer	Title
Robert Ford	Executive Chairman & CEO
Elizabeth Cushman	Executive Vice President, General Counsel & Secretary
Lisa D. Earnhardt	Executive Vice President & Group President of Medical Devices
Philip Boudreau	Chief Financial Officer & Executive Vice President of Finance

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

Quarterly EPS — Actual vs. Consensus

Beats (>2%)1 of 6recent quarters

Avg Surprise+0.8%

Next Report2026-10-21

Income Quality1.83OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Profit Margins (%)

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+24.5%	+1.3%	-8.1%	+4.6%	+5.7%
Gross profit	+33.6%	-3.8%	-10.2%	+6.4%	+15.4%
Operating income	+73.9%	-9.1%	-23.0%	+6.1%	+17.9%
Net income	+57.3%	-2.0%	-17.5%	+134.2%	-51.3%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	43.1	43.7	40.1	42.0	44.3
Cost of revenue	19.9	21.3	20.1	20.6	19.7
Gross profit	23.2	22.3	20.0	21.3	24.6
R&D expense	2.7	2.9	2.7	2.8	3.0
SG&A expense	11.3	11.1	10.9	11.7	12.4
Operating income	9.2	8.4	6.4	6.8	8.0
EBITDA	12.2	11.9	10.6	10.8	11.6
D&A	3.5	3.3	3.2	3.2	2.7
Pretax income	8.2	8.3	6.7	7.0	8.5
Income tax	1.1	1.4	0.9	-6.4	1.9
Net income	7.1	6.9	5.7	13.4	6.5
Diluted EPS ($)	3.94	3.91	3.27	7.64	3.72
Diluted shares (M)	1,789	1,764	1,749	1,748	1,747

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Operating CF$10B

CapEx$2B

Free cash flow$7B

SBC$1B

Buybacks$1B

Net cash change$1B

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	9.9	6.9	7.6	8.5
ST investments	0.3	0.4	0.4	0.4
Receivables (net)	6.2	6.6	6.9	7.9
Total current assets	25.2	22.7	23.7	26.0
PP&E (net)	10.3	11.3	11.7	12.9
Goodwill + intangibles	33.3	32.5	29.8	29.6
Total assets	74.4	73.2	81.4	86.7
Accounts payable	4.6	4.3	4.2	4.2
Short-term debt	2.5	1.3	1.8	3.3
Deferred revenue	0.0	0.0	0.0	0.0
Total current liabilities	15.5	13.8	14.2	16.5
Long-term debt	14.5	13.6	12.6	10.8
Total liabilities	37.5	34.4	33.5	33.9
Shareholders' equity	36.9	38.8	47.9	52.8

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	6.9	5.7	13.4	6.5
D&A	3.3	3.2	3.2	3.1
Stock-based compensation	0.7	0.6	0.7	0.7
Working capital change	(1.5)	(2.5)	(9.2)	(0.8)
Operating cash flow	9.6	7.3	8.6	9.6
Capital expenditures	(1.8)	(2.2)	(2.2)	(2.2)
Investing cash flow	(1.7)	(3.1)	(2.3)	(2.4)
Buybacks	(3.8)	(1.2)	(1.3)	(0.9)
Dividends paid	(3.3)	(3.6)	(3.8)	(4.1)
Debt issuance / (repay)	(0.7)	(2.5)	(0.5)	(1.6)
Financing cash flow	(7.6)	(7.1)	(5.4)	(6.3)
Free cash flow	7.8	5.1	6.4	7.4

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	20.6%	19.1%	15.2%	31.1%	13.1%	11%
ROA	9.6%	9.3%	7.8%	17.3%	7.8%	5.0%
ROIC	17.7%	15.7%	11.7%	23.9%	10.6%	6.1%
Gross margin	53.9%	51.1%	50.0%	50.8%	55.5%	56.8%
Operating margin	21.4%	19.2%	16.0%	16.3%	18.2%	17.0%
Net margin	16.4%	15.9%	14.3%	31.9%	14.7%	11.6%
EBITDA margin	28.2%	27.2%	26.4%	25.8%	26.1%	24.3%
FCF margin	20.1%	17.9%	12.6%	15.1%	16.7%	—
VALUATION
P/E	32.90	26.20	32.35	14.46	33.55	33.7
P/B	6.50	4.95	4.80	4.07	4.20	3.6
P/S	5.40	4.16	4.62	4.62	4.94	3.90
P/FCF	26.90	23.28	36.59	30.52	29.60	20.8
EV/EBITDA	19.87	15.93	18.27	18.56	19.35	18.5
EV/Revenue	5.61	4.34	4.83	4.79	5.08	4.5
Earnings yield	3.0%	3.8%	3.1%	6.9%	3.0%	2.97%
FCF yield	3.7%	4.3%	2.7%	3.3%	3.4%	4.80%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	1.85	1.63	1.64	1.67	1.58	1.38
Quick ratio	1.46	1.23	1.16	1.23	1.18	0.97
Debt / equity	0.54	0.49	0.41	0.32	0.29	0.64
Debt / assets	25.6%	24.1%	21.7%	18.8%	17.4%	29.9%
Net debt / EBITDA	0.74	0.65	0.81	0.67	0.53	2.43
Interest coverage	21.03	27.37	10.55	12.63	21.20	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	0.58	0.58	0.54	0.54	0.53	0.43
Receivables turnover	6.68	6.87	6.28	6.22	5.97	5.4
DSO (days)	55	53	58	59	61	67
DPO (days)	77	77	81	75	78	87
Cash conversion cycle	71	73	93	97	100	113
GROWTH (YoY)
Revenue growth	24.5%	1.3%	-8.1%	4.6%	5.7%	—
Net income growth	57.3%	-2.0%	-17.5%	134.2%	-51.3%	—
EPS growth	57.9%	-0.4%	-17.2%	134.4%	-51.3%	—
FCF growth	51.1%	-9.8%	-35.2%	25.5%	16.4%	—
PER SHARE ($)
EPS (diluted, TTM)	3.97	3.95	3.27	7.68	3.73	3.11
Book value / share	20.09	20.92	22.08	27.30	29.84	29.70
Revenue / share	24.17	24.89	22.95	24.03	25.37	26.73
FCF / share	4.85	4.45	2.89	3.64	4.23	5.00
Cash / share	5.75	5.80	4.16	4.56	5.12	3.21
SHAREHOLDER RETURN & SCORES
Buyback yield	1.0%	2.1%	0.7%	0.7%	0.4%	1.17%
Altman Z-Score	5.28	4.69	4.97	5.25	5.65	3.3
Piotroski F-Score	9	6	7	6	6	5/9
Beneish M-Score	-2.72	-2.65	-2.53	-2.09	-2.57	-2.69

Model	Score	Zone	Note
Piotroski F-Score	5 / 9	Middling
Altman Z-Score	3.3	Safe (>2.99)	Safe
Income quality	1.83	Cash-backed	OCF ÷ net income
Beneish M-Score	-2.69	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.72
Interest burden	0.94
Operating margin	17.2%
Asset turnover	0.48×
Financial leverage	1.90×
= ROE	11%

Growth Quality (live)	Value
Revenue stability	0.69
Earnings stability	0.04
Earnings persistence	0.50
Revenue CAGR 3y	5.0%
EPS CAGR 3y	1.8%
FCF CAGR 3y	16.7%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield1.17%

Dividend Yield2.40%

Total Shareholder Return3.76%cash yield

SBC / Revenue1.5%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
MDT	$121.2B	23.2	11%	15.1%	+9.8%	9/9	+3.0%
SYK	$113.0B	30.3	17%	19.4%	+8.5%	9/9	-20.2%
BSX	$64.3B	17.9	15%	16.7%	+13.5%	8/9	-54.6%
EW	$49.9B	49.8	9%	13.9%	+14.6%	6/9	+19.2%
DXCM	$32.5B	33.2	38%	19.0%	+15.5%	9/9	—
GILD	$193.7B	-60.1	-21%	—	+5.5%	5/9	—
PFE	$168.6B	39.1	5%	-1.6%	-0.2%	7/9	—
DHR	$161.0B	40.5	8%	13.9%	+4.6%	6/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Buy

42 Analysts

Str Sell (0)Sell (0)Hold (9)Buy (33)Str Buy (0)

Mean Target (qtr)$123.676 targets

Target vs. Price+17.9%last-quarter mean

Next Report2026-10-21street $1.42

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$50.30B	$50.44B / $50.16B	$5.52	$5.57 / $5.48	17
FY2027	$54.70B	$55.30B / $53.58B	$6.07	$6.19 / $6.01	17
FY2028	$58.51B	$59.80B / $53.84B	$6.73	$7.66 / $4.55	11

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$122.33	+16.6%	3
Last Quarter	$123.67	+17.9%	6
Last Year	$131.06	+25.0%	31
All Time	$131.56	+25.4%	80

Rolling mean of published targets vs. last close $104.88. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

B

DCF

4/5

ROE

3/5

ROA

4/5

Debt/Eq

1/5

P/E

2/5

P/B

2/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

ABT -17.8% vs S&P 500 +15.9% — spread -33.7pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$100.64	+4.24	+4.21%	Above
SMA 50	$105.74	-0.86	-0.81%	Below
SMA 200	$102.68	+2.20	+2.14%	Above
EMA 9	$101.93	+2.95	+2.89%	Above
EMA 21	$101.71	+3.17	+3.12%	Above
EMA 50	$102.59	+2.29	+2.23%	Above
EMA 200	$105.04	-0.16	-0.15%	Below

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +5519 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%89

Momentum 25%82

Volume 20%81

Volatility 10%67

Patterns 15%50

This Week91% bullishof 11 price-based votes

4 Weeks Ago9%+82 pts since

12 Weeks Ago82%+9 pts since

ReadImprovingweek-over-week trajectory

Price vs SMA 20$100.64

Price vs SMA 50$105.74

Price vs SMA 200$102.68

EMA 9/21 Cross101.9/101.7

SMA 50/200Golden

ADX DirectionADX 25

Supertrend$98

Parabolic SAR$97

SMA Slope0.110

RSI59.5

Stochastic K/D91/85

StochRSI K/D100/100

Williams %R-9

CCI136

TSI vs Signal-6.0

CMO19.1

ROC8.25%

OBV SignalAccum

Chaikin MF0.080

MFI50

Force Index6M

Elder Ray Bull4.17

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 85

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$104.74 / $105.40 / $106.11	S1 / S2	$104.03 / $103.37
Bollinger (20,2)	$95.52 – $105.76	Squeeze	Off
52-wk range	$81.97 – $132.03	Off 52-wk high	-20.6%
ATR (14)	$2.38 (2.3%)	Historical vol	23.6%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

+1.4%Jan65%

+0.5%Feb60%

-0.0%Mar52%

+0.9%Apr60%

+0.9%May55%

+1.3%Jun60%

+3.2%Jul75%

-0.2%Aug60%

+0.3%Sep50%

+0.9%Oct45%

+1.8%Nov65%

+1.7%Dec70%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	ABT	S&P 500
Weekly volatility (σ, 1y)	4.13%	1.83%
Best / worst week (1y)	+12.7% / -12.2%	—
Max drawdown (5y, monthly)	-35.6%	—
1-week VaR (95%)	-6.1%	—
Beta (5y)	0.59	1.00

ABT EQUITY WEATHER (LIVE)PARTLY CLOUDY · +16

Trend+17

Momentum+57

Volume+42

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 514 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall+15.6+35.9 vs industry

Trend+17.0+39.1 vs industry

Momentum+56.8+78.8 vs industry

Volume+41.8+46.8 vs industry

Reading	ABT	Medical - Devices n=524	Healthcare n=5,272	All US symbols n=70,435
Overall	+15.6	-20.2	-24.0	-20.5
Trend	+17.0	-22.1	-25.6	-21.3
Momentum	+56.8	-22.0	-28.5	-15.8
Volume	+41.8	-5.0	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Robert B. Ford , Chairman of the Board and C	$24.2M	44% equity+incentive
Philip P. Boudreau , Executive Vice Presiden	$9.1M	45% equity+incentive
Lisa D. Earnhardt , Executive Vice President	$8.1M	47% equity+incentive
Hubert L. Allen , Former Executive Vice Pres	$7.0M	36% equity+incentive
Christopher J. Scoggins , Executive Vice Pre	$6.6M	42% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	64
Social	57
Governance	68
Composite ESG	63

Composite ESG Trend

Filed	8-K contents	Items
2026-08-20	Regulation FD; Other Events; Exhibits	7.01,8.01,9.01
2026-07-16	Earnings Release; Exhibits	2.02,9.01
2026-04-27	Officer/Director Change; Bylaws Amendment; Shareholder Vote; Exhibits	5.02,5.03,5.07,9.01
2026-04-17	Other Events; Exhibits	8.01,9.01
2026-04-16	Earnings Release; Exhibits	2.02,9.01
2026-03-23	Other Events; Exhibits	8.01,9.01
2026-03-09	Entry into Material Definitive Agreement; Creation of Direct Financial	1.01,2.03,9.01
2026-02-26	Entry into Material Definitive Agreement; Financial Statements and Exh	1.01,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-10-21 to 2026-07-16
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	123 rows · 1995 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-08-25 to 2026-09-30
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	2 rows · 2025-12-03 to 2026-03-26
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Abbott Laboratories (ABT)

Abbott Laboratories (ABT)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Abbott Laboratories (ABT)

Institutions holding — 12 quarters

Abbott Laboratories (ABT)

Monthly Net Insider Flow (000 shares)

Signal Summary

Abbott Laboratories (ABT)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding ABT — quarterly

Institutional Put/Call — quarterly

Abbott Laboratories (ABT)

Where ABT Trades in the Dark

Abbott Laboratories (ABT)

3.8 · Employees (SEC filings)

Abbott Laboratories (ABT)

Abbott Laboratories (ABT)

Abbott Laboratories (ABT)

Balance Sheet — Full

Cash Flow Statement — Full

Abbott Laboratories (ABT)

Abbott Laboratories (ABT)

Abbott Laboratories (ABT)

Abbott Laboratories (ABT)

Street Price Target — Trajectory

Third-Party Composite Rating

Abbott Laboratories (ABT)

Abbott Laboratories (ABT)

Family Scores (site weights)

Abbott Laboratories (ABT)

Abbott Laboratories (ABT)

Abbott Laboratories (ABT)